Archive for 'Radiopharmacy'
Breakthrough treatment for neuroendocrine tumours (NETs) is now available in Belgium (Bordet Institute)
For the first time, a new form of targeted radiotherapy, or PRRT (Peptide Receptor Radio Therapy) using Lutetium-177 octreotate is available in Belgium. Thanks to a long-term endeavour of logistics, processes and national approval issues, this [...]
TRASIS (Ans, Belgium) gets global recognition with development of the first GMP (Good Manufacturing Practice) universal radiosynthesis unit
Trasis, a Belgian company experienced in the development of innovative solutions for the radiopharmaceutical industry, has joined forces with four local University laboratories in an effort to identify new types of biomarkers and tracers for in [...]
Euroscreen has recently announced the completion of a €10 million Series A preferred stock financing led by Vesalius Biocapital II Partners and SRIW(Société Régionale d’Investissement de Wallonie SA). The proceeds of the round will mainly be used to fund and develop the [...]
Exploratory efforts and supportive networks help IRE-ELiT with investigating a radiopharmacy project on Chinese soil!
The company IRE-ELiT (Fleurus, Belgium) a spin-off of IRE, could be paving the way for potential new innovative opportunities with China. IRE-ELiT has settled an agreement on an innovative project on the Chinese market for a [...]
Belgian based IBA and US investment firm SK Capital Partners have joined forces to create a promising new company, IBA Molecular Imaging. Both sides show great enthusiasm about this partnership and the potential role they will [...]
TVG is pleased to announce the launch of BioPartnering Future EUROPE (BPFE) 2012 at the 19th Annual BioPartnering Europe™, held in London this week. This new event aims to build on the hugely successful format of BPE [...]